Please login to the form below

Not currently logged in
Email:
Password:

Medivation unimpressed with Sanofi's offer

CEO says the offer “substantially undervalues” the oncology specialist
Sanofi

Medivation has broken its silence on Sanofi's $9.3bn takeover bid, saying the offer is opportunistic and is trying to "seize value" from its stockholders.

The US company issued a blunt statement indicating Sanofi's $52.50 per share bid "substantially undervalues Medivation", with chief executive David Hung pointing out that it comes during a period of market disruption and before "several important near-term events" for his company.

"Medivation has significant scarcity value as one of the few profitable, commercial-stage oncology companies," says the statement. "It has brought a blockbuster product to market and is leveraging its expertise to develop and bring to market additional products."

Last week it emerged that Sanofi has been in hot pursuit of Medivation since March, with the latter's refusal to engage with negotiations forcing the French pharma major to make its intentions public.

Sanofi is keen to get hold of Medivation for its fast-growing prostate cancer drug Xtandi (enzalutamide) - which made $1.9bn in sales last year and is growing at a phenomenal rate - as well as what is regarded as a promising oncology pipeline.

The offer has come ahead of the scheduled review date for Medivation's application to expand the use of Xtandi into a larger population of prostate cancer patients and before pivotal data on its PARP inhibitor talazoparib emerges in the first half of 2017.

"Sanofi's timing is designed to benefit Sanofi - not Medivation's stockholders," asserts the US firm.

In response to Medivation's refusal, Sanofi issued its own short statement in which it reiterated that the takeover "represents a compelling strategic and financial opportunity to drive immediate and certain value" for the shareholders of both companies.

"Sanofi is a disciplined acquirer and has a strong acquisition track-record," it added.

Meanwhile, there is increasing speculation among market watchers that other companies may be emboldened to step forward with their own offers for Medivation, with Bloomberg suggesting Novartis, Pfizer and AstraZeneca are all interested in making a bid.

Article by
Phil Taylor

3rd May 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....

Infographics